InMed Pharmaceuticals
INMInMed Pharmaceuticals Inc. (NASDAQ: INM) is a clinical-stage biopharmaceutical company based in Canada. The company’s business is focused on two integrated pillars: the development of cannabinoid-based pharmaceutical drug candidates and the manufacturing of rare cannabinoids for biomedical research and other applications. Its proprietary biosynthesis manufacturing platform, IntegraSyn™, is designed for the scalable and consistent production of rare cannabinoids, which are difficult to source in meaningful quantities from traditional plant extraction. The company’s therapeutic development pipeline targets diseases with high unmet medical need. Its lead clinical candidate, INM-755, is being evaluated for the treatment of epidermolysis bullosa, a rare genetic skin disorder. A second candidate, INM-088, is in preclinical development targeting ocular diseases, specifically glaucoma. InMed’s research and development efforts are centered on leveraging the pharmacological properties of specific cannabinoids to address complex conditions through a defined pharmaceutical approach. As a publicly traded entity, InMed Pharmaceuticals operates within the biotech and pharmaceutical sectors, advancing its programs through clinical and preclinical studies. The company’s activities encompass both drug development for specific patient populations and the supply of cannabinoid ingredients for the broader scientific and commercial markets.
INM · Stock Price
Historical price data
About
InMed Pharmaceuticals Inc. (NASDAQ: INM) is a clinical-stage biopharmaceutical company based in Canada. The company’s business is focused on two integrated pillars: the development of cannabinoid-based pharmaceutical drug candidates and the manufacturing of rare cannabinoids for biomedical research and other applications. Its proprietary biosynthesis manufacturing platform, IntegraSyn™, is designed for the scalable and consistent production of rare cannabinoids, which are difficult to source in meaningful quantities from traditional plant extraction. The company’s therapeutic development pipeline targets diseases with high unmet medical need. Its lead clinical candidate, INM-755, is being evaluated for the treatment of epidermolysis bullosa, a rare genetic skin disorder. A second candidate, INM-088, is in preclinical development targeting ocular diseases, specifically glaucoma. InMed’s research and development efforts are centered on leveraging the pharmacological properties of specific cannabinoids to address complex conditions through a defined pharmaceutical approach. As a publicly traded entity, InMed Pharmaceuticals operates within the biotech and pharmaceutical sectors, advancing its programs through clinical and preclinical studies. The company’s activities encompass both drug development for specific patient populations and the supply of cannabinoid ingredients for the broader scientific and commercial markets.